Clinical Trials Logo

Respiratory Distress Syndrome clinical trials

View clinical trials related to Respiratory Distress Syndrome.

Filter by:

NCT ID: NCT05718830 Completed - Inhalation Injury Clinical Trials

Selecting Specific Bio-markers and Researching Mechanisms of Immune Regulation From Inhalation Injury and Traumatic Lung Injury Based on Single Cell Sequencing Technology

Start date: January 1, 2021
Phase:
Study type: Observational

The goal of this observational study is to profile the circulating immunological traits of patients with traumatic lung injury (TLI) and inhalation injury (ILI),providing a new direction for the depth research of the pathogenesis, and providing new immune-related targets for diagnosis of the severity of lung injury and treatment. The investigators performed scRNA-seq of neutrophil and peripheral blood mononuclear cells (PBMCs) from 10 ml fresh circulating blood from 3 patients with TLI and 3 patients with ILI at longitudinal timepoints,as well as peripheral blood from 3 health controls(HCs).

NCT ID: NCT05717218 Recruiting - Severe ARDS Clinical Trials

Ultra-protective Ventilation Monitored by Electrical Impedance Tomography in Patients With Severe Acute Respiratory Distress Syndrome on Veno-venous ECMO

EIT-ECMO
Start date: March 11, 2023
Phase: N/A
Study type: Interventional

For ECMO supported patients with severe ARDS (acute respiratory distress syndrome), usual care include use of "ultraprotective" mechanical ventilation with tidal volume and pressure reductions that might ultimately enhance lung protection of patients with ARDS. Although very low tidal might also cause pulmonary derecruitment. The aim of this study is to monitor effects of very low tidal volume on regression of overdistension and derecruitment using electrical impedance tomography. Secondary aim is to describe the evolution of the optimal PEEP (Positive End Expiratory Pressure) during the decrease of the tidal volume

NCT ID: NCT05715788 Recruiting - Clinical trials for Respiratory Distress Syndrome

Prone Positioning vs. Prone Positioning and NO Inhalation in COVID-19 ARDS.

Start date: December 21, 2022
Phase:
Study type: Observational

The investigators aim to investigate the effects of prone positioning and prone positioning with NO inhalation for COVID-19 patients with ARDS.

NCT ID: NCT05715762 Recruiting - COVID-19 Clinical Trials

Determine the Effects of Prone Positioning and NO in COVID-19 ARDS by EIT

Start date: December 21, 2022
Phase:
Study type: Observational [Patient Registry]

We aims to investigate the effects of prone positioning and nitric oxide inhalation in adult patients who is diagnosed with COVID-19 associated acute respiratory distress syndrome by electrical impedance tomography.

NCT ID: NCT05714865 Recruiting - Clinical trials for Respiratory Distress Syndrome

Implementing LISA Surfactant in Nigeria

Start date: June 25, 2023
Phase: Phase 4
Study type: Interventional

Implement surfactant (BLES®) replacement therapy using the Less Invasive Surfactant Administration technique in six tertiary institutions in Nigeria and evaluate its impact on 72-hour neonatal mortality in premature infants born less than 2000 grams at birth.

NCT ID: NCT05711966 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Comparison of INRECSURE and LISA in Preterm Neonates With RDS

INRECLISA
Start date: January 9, 2023
Phase: N/A
Study type: Interventional

The primary hypothesis of this study is that surfactant administration by INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E), via a high frequency oscillatory ventilation recruitment maneuver increases survival without BPD at 36 weeks' gestational age in spontaneously breathing infants born at 24+0-27+6 weeks' gestation affected by Respiratory Distress Syndrome (RDS) and failing nasal CPAP or nasal intermittent positive pressure ventilation (NIPPV) during the first 24 hours of life compared to less invasive surfactant administration (LISA).

NCT ID: NCT05699889 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS

URICOV
Start date: May 2, 2020
Phase:
Study type: Observational

In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not known at this time. The consequences of Covid-19 on renal function in the short and long term are not known. It is important to be able to better document these renal impairments to understand the mechanisms of this disease. The main objective of this study is to describe the prevalence of Covid-19-related renal damage (acute renal failure, proteinuria, microalbuminuria, hematuria) in a large cohort of patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment. The other objectives will be to evaluate in this cohort the impact of these renal impairments on the severity of the Covid-19 disease, and to compare them to the renal impairments of patients in intensive care for acute respiratory distress syndrome (ARDS) due to other respiratory diseases. Blood and urine samples will be taken at the time of intubation in all critically ill patients with respiratory distress requiring mechanical ventilation for Covid-19 or other cause of respiratory distress with PaO2/FiO2 ratio < 300. Patients will be followed for the duration of their ICU and hospital stay. Data will be collected prospectively in three ICUs in the University Hospitals of Marseille.

NCT ID: NCT05697666 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients

Start date: February 1, 2020
Phase:
Study type: Observational

Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory mechanics by reducing ventilator induced lung injuries (VILI), especially the so called atelectrauma. Although its monitoring is recommended in clinical practice, data about the depth of NMB necessary for an effective relaxation of the thoracic and diaphragmatic muscles and, therefore, the reduction of the chest wall elastance, are scarce. The investigators hypothesised that complete versus partial NMB can modify respiratory mechanics and its partitioning.

NCT ID: NCT05697016 Not yet recruiting - Respiratory Failure Clinical Trials

Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19

Start date: January 31, 2023
Phase: N/A
Study type: Interventional

A randomized, double-Blind, placebo-controlled trial aimed to investigate the safety and efficacy of sivelestat on treating adult patients with COVID-19-related acute respiratory distress syndrome (ARDS)

NCT ID: NCT05693051 Completed - ARDS, Human Clinical Trials

Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO

Start date: October 1, 2020
Phase:
Study type: Observational

Prone position ventilation was used 220 times in 44 out of 68 patients with severe COVID-19 induced ARDS treated with VV-ECMO. PPV treated patients did not benefit from PPV and the incidence of PPV related adverse events was high